Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Clover Biopharmaceuticals, Ltd.

三葉草生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2197)

VOLUNTARY ANNOUNCEMENT COVID-19 VACCINE (SCB-2019 (CPG 1018/ALUM)) INCLUDED FOR EMERGENCY USE IN THE PRC

This announcement is made by the board (the "Board") of directors (the "Directors") of Clover Biopharmaceuticals, Ltd. (the "Company" or "Clover", together with its subsidiaries, the "Group") on a voluntary basis to inform the shareholders of the Company and potential investors on the latest development status of the core product of the Group.

Clover is pleased to announce that the Company's lead COVID-19 vaccine, SCB-2019 (CpG 1018/Alum), has been evaluated by relevant authorities of the People's Republic of China (the "PRC") and included for emergency use in the PRC.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will be able to ultimately commercialize SCB-2019 (CpG 1018/Alum) successfully.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Clover Biopharmaceuticals, Ltd.
Dr. Peng LIANG
Chairman of the Board

Shanghai, PRC, December 5, 2022

As of the date of this announcement, the Board comprises Dr. Peng LIANG and Mr. Joshua G LIANG as executive Directors; Dr. Xiaodong WANG, Dr. Donna Marie AMBROSINO and Dr. Ralf Leo CLEMENS as non-executive Directors; and Dr. Xiaobin WU, Mr. Xiang LIAO, Mr. Jeffrey FARROW and Mr. Thomas LEGGETT as independent non-executive Directors.